Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metoprolol on Thalassemia Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented LVEF \< 50% by echocardiography~* B thalassemia~* No decompensated heart failure for at least 4 weeks (hospitalization for CHF, worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)~* have no evidence of acute myocarditis and~* hemoglobin level above 7 gr⁄dL.~Exclusion Criteria:~* pulse rate below 60/min~* systolic blood pressure less than 90 mmHg~* evidence of peripheral vascular disease~* major depression, history of asthma, PR interval more than 240 msec, second or third degree AV block~* major medical diseases including diabetes mellitus requiring insulin injection, hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for human immunodeficiency virus, and other hemoglobinopathies

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- metoprolol (Type: ACTIVE_COMPARATOR): patient or intervention group
- placebo group (Type: ACTIVE_COMPARATOR): control group

Based on this trial design, predict the completion outcome and termination type (if applicable).